TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20887535

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with fathers for 30 minutes after initial 5 minutes with mothers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact with mothers for 30 minutes after initial 5 minutes with mothers
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (fathers and mothers without skin-to-skin contact)
Number of subjects: 37
Study: 18237297

Group type: EXPERIMENTAL
Intervention: Computerized device (Wand, Milestone Scientific)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional plastic syringe
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pre-injection anxiety levels
Number of subjects: 41
Study: 16623830

Group type: EXPERIMENTAL
Intervention: Implicit mirror-tracing learning task
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Explicit word-pair association learning task
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control task (corresponding to learning tasks)
Number of subjects: 48
Study: 14725135

Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reassurance by nurse practitioner
Number of subjects: 36
Study: 11106143

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg in a controlled-release formulation)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9064946

Group type: COMPARATOR
Intervention: Dobutamine (maximal dose: 9 micrograms/kg/min; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milrinone (0.5 microgram/kg/min; n = 10)
Number of subjects: 20
Study: 1370510

Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with alum-precipitated aqueous ragweed extracts
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study: 6383654

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (average dose 845,000 U iv, administered at 2.8 ± 1.0 hr after onset of pain)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (average dose 212,000 U ic, administered at 4.3 ± 1.4 hr after onset of pain)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Historical control group (not specified dosage or timing)
Number of subjects: 50
Study: 31521917

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Coordinative training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 92
Study: 30261892

Group type: EXPERIMENTAL
Intervention: Soluble keratin (KER) 0.8 g/kg bodyweight/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Casein protein (CAS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Soluble keratin (KER)
Number of subjects: 15
Study: 26817502

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg Zn/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (5 mg Zn/d)
Number of subjects: 31
Study: 24472253

Group type: EXPERIMENTAL
Intervention: 8 weeks of preschool-based social communication treatment in addition to standard preschool program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard preschool program only
Number of subjects: 61
Study: 23257132

Group type: EXPERIMENTAL
Intervention: Qianggu Capsule and two disease-modifying antirheumatic drugs
Number of subjects: 82

Group type: COMPARATOR
Intervention: Two common-used antirheumatic drugs
Number of subjects: 82
Study: 20698724

Group type: EXPERIMENTAL
Intervention: 1.3 g tranexamic acid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3.9 g tranexamic acid
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.4 g moxifloxacin (positive control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study: 17686152

Group type: EXPERIMENTAL
Intervention: rFVIIa (200 + 100 + 100 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15458612

Group type: EXPERIMENTAL
Intervention: Hypericum extract (HE) 900 mg/d
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 12467852

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound waveform estimation
Number of subjects: 204
Study: 10432323

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 480
Study: 7594327

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg and clarithromycin 400 mg (group 1, n = 22)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg and clarithromycin 800 mg (group 2, n = 12)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg and clarithromycin 800 mg (group 3, n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (n = 23)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lansoprazole 60 mg (n = 13)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Omeprazole 20 mg (n = 15)
Number of subjects: 58
Study: 2110788

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 160348

Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sulindac 100 mg twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg thrice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Soluble aspirin 600 mg thrice daily
Number of subjects: 46
Study: 30512122

Group type: EXPERIMENTAL
Intervention: Fab antivenom (FabAV)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 27785095

Group type: EXPERIMENTAL
Intervention: Nattokinase (100 mg/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 23881520

Group type: EXPERIMENTAL
Intervention: Stepped Care Program (SCP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 136
Study: 24337425

Group type: EXPERIMENTAL
Intervention: New back school intervention
Number of subjects: 88
Study: 20452366

Group type: EXPERIMENTAL
Intervention: Sustained Attention to Response Task (SART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SART
Number of subjects: 0
Study: 18549711

Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 16094519

Group type: EXPERIMENTAL
Intervention: Equimolar mixture of nitrous oxide/oxygen (EMNO)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo mixture (50% oxygen and 50% nitrogen)
Number of subjects: 83
Study: 11167594

Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy (including chemotherapy)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: More than one course of chemotherapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Adjuvant systemic therapy
Number of subjects: 86
Study: 9728898

Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 gm/day for 2 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day for 2 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8050255

Group type: EXPERIMENTAL
Intervention: Patient-specific letters
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Postcard reminders
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 288
Study: 3056820

Group type: EXPERIMENTAL
Intervention: Portal-systemic shunt
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 81
Study: 1424416

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-alcohol
Number of subjects: 12
Study: 277253

Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of hyperbaric oxygen and misonidazole
Number of subjects: 0
Study: 30095536

Group type: EXPERIMENTAL
Intervention: Opicinumab (100 mg/kg intravenous every 4 weeks for 6 infusions)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 27654466

Group type: EXPERIMENTAL
Intervention: Pre-operative vacuum erection device (VED) use; 10-15 min/day for ≥30 days (Group A)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No intervention (Group B)
Number of subjects: 51
Study: 25805530

Group type: EXPERIMENTAL
Intervention: Modified Mental Health Experience Co‐Design (MH ECO) intervention
Number of subjects: 330
Study: 23640743

Group type: EXPERIMENTAL
Intervention: Dietary weight loss (N = 118)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (N = 117)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Diet + exercise (N = 117)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study: 21487327

Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐HBV‐IPV/Hib
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐IPV‐Hib
Number of subjects: 780

Group type: COMPARATOR
Intervention: 7‐valent pneumococcal conjugate vaccine + DTPa‐IPV‐Hib
Number of subjects: 780
Study: 19555810

Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg BID)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Naproxen (500 mg BID)
Number of subjects: 103
Study: 17588421

Group type: EXPERIMENTAL
Intervention: Chest drain
Number of subjects: 60

Group type: COMPARATOR
Intervention: No chest drain
Number of subjects: 60
Study: 15530999

Group type: COMPARATOR
Intervention: Carisoprodol
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclobenzaprine hydrochloride
Number of subjects: 197

Group type: COMPARATOR
Intervention: Metaxalone
Number of subjects: 197
Study: 12370851

Group type: EXPERIMENTAL
Intervention: Meals rich in safflower and olive oils
Number of subjects: 21
Study: 9824786

Group type: EXPERIMENTAL
Intervention: Rifampicin 300 mg/day for 10 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg/day for 10 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control cycle (no rifampicin or rifabutin)
Number of subjects: 28
Study: 8131225

Group type: EXPERIMENTAL
Intervention: Ambulance officers at 30 cm H2O
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulance officers at 20 cm H2O
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anaesthetists with a two-handed grip
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambulance officers and anaesthetists
Number of subjects: 0
Study: 2509069

Group type: EXPERIMENTAL
Intervention: Netilmicin 300 mg once daily (group A)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Netilmicin 100 mg three times daily (group B)
Number of subjects: 185
Study: 1102329

Group type: EXPERIMENTAL
Intervention: d,1-oxyphedrine (myophedrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1-oxyphedrine
Number of subjects: 0
Study: 31898756

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) cheek fillers injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thread lifting for the cheek
Number of subjects: 20
Study: 30825454

Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroquinone
Number of subjects: 0
Study: 28109247

Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based intervention (IMI) for depression prevention, based on cognitive behavioral therapy (CBT) principles, comprising six weekly modules and two booster sessions.
Number of subjects: 406

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 406
Study: 25418126

Group type: EXPERIMENTAL
Intervention: SSE plus mobile teledermoscopy with detailed SSE instructions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Clinical skin examination (CSE)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SSE plus mobile teledermoscopy
Number of subjects: 58
Study: 23523432

Group type: EXPERIMENTAL
Intervention: Sleep extension group (gradual sleep extension by advancing bedtimes in the evening)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sleep extension group
Number of subjects: 55
Study: 21125678

Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 19424811

Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 644

Group type: COMPARATOR
Intervention: Evidence-based communication
Number of subjects: 644

Group type: COMPARATOR
Intervention: Patient-based intervention
Number of subjects: 644

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 644
Study: 17265017

Group type: EXPERIMENTAL
Intervention: P-STIM-verum
Number of subjects: 44

Group type: COMPARATOR
Intervention: P-STIM-placebo
Number of subjects: 44
Study: 15243610

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:100,000 adrenaline
Number of subjects: 20
Study: 11552276

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass during CABG
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass without chronic renal failure (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Long-term survival
Number of subjects: 64
Study: 9572900

Group type: EXPERIMENTAL
Intervention: Colon-Targeted Delivery Capsule
Number of subjects: 0
Study: 7922092

Group type: EXPERIMENTAL
Intervention: Triple therapy (prednisolone, cyclosporin A, azathioprine)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Prednisolone with cyclosporin
Number of subjects: 492

Group type: COMPARATOR
Intervention: Azathioprine with prednisolone
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin, azathioprine, and prednisolone
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin and prednisolone
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin, nifedipine, and prednisolone
Number of subjects: 492
Study: 3136953

Group type: COMPARATOR
Intervention: Heparin alone (27 patients)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Maintenance infusion of rt-PA at 0.8 mg/kg during 4 hours (25 patients)
Number of subjects: 68
Study: 31713266

Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG laser treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 23
Study: 30587761

Group type: EXPERIMENTAL
Intervention: 250 mg/day of elemental Mg for three months
Number of subjects: 42
Study: 26474452

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 637

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 637
Study: 22922662

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with anterior chamber maintainer and adjustable sutures (technique 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Trabeculectomy with viscoelastic and solely releasable sutures (technique 2)
Number of subjects: 32
Study: 23327125

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 0.2 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo (PLC)
Number of subjects: 8
Study: 21265297

Group type: EXPERIMENTAL
Intervention: Sleep-deprived (SD)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: SD + energy deficit
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: SD + energy deficit + fluid restricted
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 18785308

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 82
Study: 15941886

Group type: EXPERIMENTAL
Intervention: Plant sterols (1.8 g/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cornstarch placebo
Number of subjects: 29
Study: 12912695

Group type: EXPERIMENTAL
Intervention: Clinical measurement of longest basal diameter
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Echographic measurement of apical height
Number of subjects: 644

Group type: COMPARATOR
Intervention: Histopathological measurement of longest basal diameter
Number of subjects: 644

Group type: COMPARATOR
Intervention: Histopathological measurement of apical height
Number of subjects: 644
Study: 10622655

Group type: EXPERIMENTAL
Intervention: Felodipine infusion during the hypothermic period of cardiopulmonary bypass
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no felodipine infusion)
Number of subjects: 22
Study: 8622115

Group type: EXPERIMENTAL
Intervention: Isepamicin (8 or 15 mg/kg once daily)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Amikacin (7.5 mg/kg twice daily)
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Isepamicin (7.5 mg/kg twice daily)
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: Isepamicin and Amikacin
Number of subjects: 1443
Study: 1827614

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7028935

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 micrograms/kg/minute
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30268546

Group type: EXPERIMENTAL
Intervention: Stand-alone porous tantalum cage
Number of subjects: 57

Group type: COMPARATOR
Intervention: Autologous bone graft and plating
Number of subjects: 57
Study: 28933613

Group type: EXPERIMENTAL
Intervention: Partnered ballroom dancing, 1 hour, twice a week for 10 weeks, led by professional dance teachers.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group received dance class vouchers at the end of the study.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Blinded assessments of balance, mobility, and function were completed in the home.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6-minute walk test at six months proposed for Phase III trial.
Number of subjects: 51
Study: 27253335

Group type: EXPERIMENTAL
Intervention: General Exercise (GE)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Core Stability Exercise (CSE)
Number of subjects: 43
Study: 24836310

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study: 21999424

Group type: EXPERIMENTAL
Intervention: Portable laparoscopic trainer
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standardized laparoscopic trainer
Number of subjects: 29
Study: 20575920

Group type: EXPERIMENTAL
Intervention: Mask group (all non-scrubbed staff wore a mask)
Number of subjects: 827

Group type: COMPARATOR
Intervention: No Mask group (none of the non-scrubbed staff wore masks)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 827

Group type: COMPARATOR
Intervention: Mask group vs No Mask group
Number of subjects: 827
Study: 18270675

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine (0.25 mg/kg BW bolus followed by infusion of 0.06 mg/kg BW/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol infusion (>3 mg/kg BW/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16159610

Group type: EXPERIMENTAL
Intervention: Tocotrienol rich fraction (TRF)
Number of subjects: 19
Study: 12548585

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamidronate 90 mg
Number of subjects: 0
Study: 10549452

Group type: EXPERIMENTAL
Intervention: Foaming tablet
Number of subjects: 765

Group type: COMPARATOR
Intervention: Nonoxynol-9 film
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Both spermicides
Number of subjects: 765
Study: 8561056

Group type: EXPERIMENTAL
Intervention: Hypoenergetic diet (2508‐kJ/d or 600 kcal/d) for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ad libitum diet for 4 weeks (Control)
Number of subjects: 14
Study: 8154255

Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia with 150 I.U. hyaluronidase (Kinetin) added to 4 mg lidocaine 2% with adrenalin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia without hyaluronidase (Control)
Number of subjects: 80
Study: 3537872

Group type: EXPERIMENTAL
Intervention: Nurture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vitamilk
Number of subjects: 100
Study: 30864361

Group type: EXPERIMENTAL
Intervention: Scalpel (cold steel surgical scalpel №15)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrosurgery (electrosurgical microneedle with 0.06mm tip radius, power 12 W)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 80
Study: 26797718

Group type: EXPERIMENTAL
Intervention: Pre-operative nutritional status assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-operative dietary intake
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Micronutrient intake
Number of subjects: 100
Study: 24882370

Group type: EXPERIMENTAL
Intervention: Spa treatment combined with consultation with dietician
Number of subjects: 181

Group type: COMPARATOR
Intervention: Consultations with dietician only
Number of subjects: 181
Study: 25138814

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 228

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 228
Study: 21875316

Group type: EXPERIMENTAL
Intervention: Self-ligating (SC) bracket
Number of subjects: 19

Group type: COMPARATOR
Intervention: Modified twin design (MT) bracket
Number of subjects: 19
Study: 19535425

Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) for 90 days
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) with multivitamins and/or anthelminthics
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Iron (25 mg) and folic acid (100 microg) with adherence higher than the median
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: High-dose daily iron+folic acid
Number of subjects: 462
Study: 17595891

Group type: EXPERIMENTAL
Intervention: 5 mg rivaroxaban once, twice or three times daily, or 10, 20 or 30 mg rivaroxaban twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plasma concentrations
Number of subjects: 0